PD Program
Parkinson's Disease
DiscoveryActive
Key Facts
About Lunai Bioworks
Lunai Bioworks is a public biotech company (LNAI) on a mission to decode disease biology by creating a continuous, integrated system where AI-driven insights are rapidly validated in living models. Founded in 2021, the company has developed a validated platform combining its Augusta AI engine, Phenograph translational system, and high-throughput zebrafish models to identify novel therapeutic targets and biomarkers. Its strategy focuses on advancing internal programs and strategic partnerships in complex therapeutic areas like oncology and neurology, aiming to compress drug discovery timelines and reduce clinical attrition.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |
| golexanolone | Umecrine Cognition | Preclinical |
| Bezisterim (NE3107) | BioVie | Phase 2 |
| Cannabinoid-based Therapy | Gb Sciences | Preclinical |